药物发现的新方法 872条(本栏目收费,不能显示细节,电话15274084725)
concentration–time profile, 244 244
target validation, 239 239
therapeutic window, 253–254 254
PH Groups 1 (PAH), 228, 229 229
Phospholipidosis, 275 275
Phototoxicity, 274–275 275
Physiologically based PK (PBPK) model, 246,316–318 318
Pitstops 1 and 4, 130, 131 131
PK. See Pharmacokinetics (PK) 0
PKS. See Polyketide synthetases (PKS) 0
Plants, natural products, 94–95 95
Plate-based screening, 34 34
Polyketide synthetases (PKS), 105, 106 106
Positional-scanning synthetic-peptide combinatorial library (PS-SPCL),77–78 78
PPIs. See Protein–protein interactions (PPIs) 0
PRA. See Progesterone receptor antagonists (PRA) Pravastatin, 95, 96 96
Preclinical animal models, 66–67 67
Preclinical oncology 2D cell cultures, 215 215
drug discovery process, 204, 205 205
humanized mice model, 211 211
lead identification and optimization 0
mouse and rat strains, 209–211 211